IGM Biosciences, Inc. Employee Directory
Biotechnology ResearchCalifornia, United States51-200 Employees
IGM Biosciences is a clinical-stage biotechnology company focused on developing a new class of antibody medicines for autoimmune and inflammatory diseases. The company works with engineered Immunoglobulin M antibodies, which have ten binding sites and are designed to achieve high selectivity and avidity compared with conventional antibodies. It holds an exclusive worldwide collaboration with Sanofi to create, develop, manufacture, and commercialize IgM antibody agonists across oncology, immunology, and inflammation targets, and is based in Mountain View, California. Its pipeline includes Imvotamab, a bispecific IgM antibody targeting CD20 and CD3, being explored in Phase 1b for severe systemic lupus erythematosus, rheumatoid arthritis, and myositis. In early 2025, the company announced it would halt further development of Imvotamab and IGM-2644 for autoimmune diseases, signaling a strategic shift in its program.